ANI PHARMACEUTICALS, INC
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $266.0M | $237.5M | $247.1M | $227.8M | $211.4M | $197.1M | $190.6M | $148.3M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $14.7M | $10.6M | $12.3M | $12.3M | $16.5M | $10.6M | $16.6M | $10.1M |
| SG&A Expense | $91.7M | $73.7M | $82.8M | $76.7M | $81.8M | $76.5M | $69.7M | $79.1M |
| Operating Income | $40.5M | $38.9M | $34.8M | $36.2M | $13.9M | $26.2M | $-4.4M | $-20.5M |
| Operating Margin | 15.2% | 16.4% | 14.1% | 15.9% | 6.6% | 13.3% | -2.3% | -13.8% |
| Interest Expense | $7.5M | $7.6M | $8.0M | $8.3M | $8.2M | $8.1M | $8.8M | $6.7M |
| Pretax Income | $37.1M | $40.2M | $31.5M | $33.8M | $10.5M | $20.0M | $-13.8M | $-31.5M |
| Income Tax Expense | $12.4M | $10.7M | $4.0M | $7.2M | $2.0M | $4.3M | $-3.5M | $-7.3M |
| Net Income | $24.7M | $29.5M | $27.5M | $26.6M | $8.5M | $15.7M | $-10.3M | $-24.2M |
| Net Margin | 9.3% | 12.4% | 11.1% | 11.7% | 4.0% | 8.0% | -5.4% | -16.3% |
| EPS (Basic) | $1.09 | $1.31 | $1.24 | $1.19 | $0.37 | $0.70 | $-0.47 | $-1.27 |
| EPS (Diluted) | $1.05 | $1.28 | $1.14 | $1.13 | $0.36 | $0.69 | $-0.45 | $-1.27 |
| Shares Outstanding (Basic) | 21.2M | 20.9M | 20.1M | 20.1M | 19.8M | 19.6M | 19.3M | 19.4M |
| Shares Outstanding (Diluted) | 21.9M | 21.5M | 21.2M | 21.1M | 20.3M | 20.0M | 19.3M | 19.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |